Myanmar Drug Market Valued At $120 Million, Set To Grow At 15% Rate
This article was originally published in PharmAsia News
Myanmar's new market for drugs and medical devices is nearing the $120 million level, with only 10 domestic companies competing against imports that fill about 90% of the nation's needs.
You may also be interested in...
Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.
The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.